CSL’s earnings jump as blood plasma products boom
Biotechnology giant CSL has reported net profit after tax for the six months ended December 31 of $1.9 billion, up 20 percent on the previous corresponding period. Underlying net profit was $2.02, set on revenue up 11 percent to $8.05 billion. CSL CEO and Managing Director Dr Paul McKenzie said: “Our strong first half result…